GLP-1 Pharmacotherapy for Obesity

Endocrinologist-led GLP-1 receptor agonist pharmacotherapy for medically supervised obesity management. Weight loss medications are used as adjuvant therapy to lifestyle changes and are carefully monitored throughout treatment.

GLP-1 (glucagon-like peptide-1) receptor agonists represent one of the most significant advances in obesity pharmacotherapy in recent decades, and the SGH Obesity Centre is at the forefront of their clinical use in Singapore. These medications — which include agents such as semaglutide and liraglutide — work by mimicking the natural GLP-1 hormone to suppress appetite, slow gastric emptying, and improve insulin sensitivity, resulting in meaningful and sustained weight reduction alongside metabolic benefits. At the SGH Obesity Centre, GLP-1 pharmacotherapy is initiated and managed exclusively by endocrinologists — specialists in hormonal and metabolic disease — ensuring that prescribing decisions are grounded in a thorough understanding of each patient's metabolic profile, comorbidities, and treatment history. This is not a private clinic quick-prescribe service; rather, it is a rigorous medical programme where pharmacotherapy is deployed as a targeted intervention within a broader weight management strategy. Patients begin with a comprehensive metabolic assessment including blood glucose regulation, HbA1c, lipid profile, liver function, and cardiovascular risk evaluation. The endocrinologist determines whether GLP-1 therapy is clinically appropriate and, if so, which agent and dose titration schedule will best balance efficacy with tolerability. Common side effects such as nausea are carefully managed through graduated dosing protocols. Throughout the treatment period, patients are monitored at regular intervals to assess weight loss trajectory, metabolic marker improvement, medication tolerance, and any emerging side effects. Dose adjustments are made based on response. The SGH Obesity Centre views GLP-1 therapy as one component of a comprehensive plan — it is used in combination with dietary counselling, physical activity guidance, and where appropriate, psychological support — to maximise outcomes and ensure that weight loss is sustainable beyond the treatment period. For patients with type 2 diabetes and obesity, GLP-1 receptor agonists offer the additional benefit of glycaemic control, making them a particularly compelling option for those managing both conditions simultaneously. The centre's endocrinologists are experienced in optimising GLP-1 regimens for patients across this complex clinical intersection.